1. Home
  2. SCLX vs VATE Comparison

SCLX vs VATE Comparison

Compare SCLX & VATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCLX
  • VATE
  • Stock Information
  • Founded
  • SCLX 2011
  • VATE 1994
  • Country
  • SCLX United States
  • VATE United States
  • Employees
  • SCLX N/A
  • VATE N/A
  • Industry
  • SCLX Biotechnology: Pharmaceutical Preparations
  • VATE Metal Fabrications
  • Sector
  • SCLX Health Care
  • VATE Industrials
  • Exchange
  • SCLX Nasdaq
  • VATE Nasdaq
  • Market Cap
  • SCLX 61.5M
  • VATE 63.4M
  • IPO Year
  • SCLX N/A
  • VATE 1996
  • Fundamental
  • Price
  • SCLX $0.33
  • VATE $10.81
  • Analyst Decision
  • SCLX Strong Buy
  • VATE
  • Analyst Count
  • SCLX 4
  • VATE 0
  • Target Price
  • SCLX $14.00
  • VATE N/A
  • AVG Volume (30 Days)
  • SCLX 184.3K
  • VATE 158.6K
  • Earning Date
  • SCLX 03-11-2025
  • VATE 03-03-2025
  • Dividend Yield
  • SCLX N/A
  • VATE N/A
  • EPS Growth
  • SCLX N/A
  • VATE N/A
  • EPS
  • SCLX N/A
  • VATE N/A
  • Revenue
  • SCLX $55,152,000.00
  • VATE $1,231,500,000.00
  • Revenue This Year
  • SCLX $24.19
  • VATE N/A
  • Revenue Next Year
  • SCLX $109.90
  • VATE N/A
  • P/E Ratio
  • SCLX N/A
  • VATE N/A
  • Revenue Growth
  • SCLX 22.02
  • VATE N/A
  • 52 Week Low
  • SCLX $0.32
  • VATE $3.25
  • 52 Week High
  • SCLX $2.63
  • VATE $13.79
  • Technical
  • Relative Strength Index (RSI)
  • SCLX 30.09
  • VATE 50.34
  • Support Level
  • SCLX $0.33
  • VATE $11.60
  • Resistance Level
  • SCLX $0.36
  • VATE $13.79
  • Average True Range (ATR)
  • SCLX 0.03
  • VATE 1.03
  • MACD
  • SCLX -0.00
  • VATE -0.31
  • Stochastic Oscillator
  • SCLX 8.90
  • VATE 2.30

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments which are; The infrastructure segment is comprised of DBM Global Inc, a fully integrated industrial construction, structural steel, and facility maintenance provider that provides fabrication and erection of structural steel and heavy steel plate services, The Life Sciences segment is comprised of Pansend Life Sciences which seeks to develop products to treat early osteoarthritis of the knee and aesthetic and medical technologies for the skin, and Spectrum segment is comprised of HC2 Broadcasting Holdings Inc which operates over-the-air broadcasting stations across the United States.

Share on Social Networks: